Navigation Links
New light on bipolar treatment drugs
Date:4/20/2009

Lithium has been established for more than 50 years as one of the most effective treatments for bipolar mood disorder.

However, scientists have never been entirely sure exactly how it operates in the human brain.

Now, new research from Cardiff University scientists suggests a mechanism for how Lithium works, opening the door for potentially more effective treatments.

Laboratory tests on cells have shown that Lithium affects a molecule called PIP3 that is important in controlling brain cell signalling. Lithium suppresses the production of inositol, a simple sugar from which PIP3 is made.

Lithium inhibits inositol monophosphatase (IMPase) an enzyme required for making inositol. Importantly, this research shows that increasing the amount of IMPase causes higher levels of PIP3. This can then be reduced by lithium treatment.

High levels of IMPA2, a gene for a variant of IMPase, has previously been linked to bipolar mood disorder. This new result suggests that Lithium could counteract the changes in IMPA2.

Professor Adrian Harwood of Cardiff School of Biosciences, who led the research, said: "We still cannot say definitively how Lithium can help stabilise bipolar disorder. However, our research does suggest a possible pathway for its operation. By better understanding Lithium, we can learn about the genetics of bipolar disorder and develop more potent and selective drugs.

"Further, altered PIP3 signalling is linked to other disorders, including epilepsy and autism, so this well established drug could be used to treat other conditions. Research into Lithium could become very important over the next few years."

Lithium is currently under clinical trial for the treatment of neurogenerative disorder amyotrophic lateral sclerosis (ALS)

The research, funded by the Wellcome Trust, is published in the journal Disease Models and Mechanisms.


'/>"/>

Contact: Professor Adrian Harwood
harwoodaj@cardiff.ac.uk
44-029-208-79358
Cardiff University
Source:Eurekalert

Page: 1

Related biology news :

1. Singapore scientists synthesize gold to shed light on cells inner workings
2. Home tooth bleaching slightly reduces enamel strength
3. Genes from tiny algae shed light on big role managing carbon in worlds oceans
4. Queens researchers shine light on compact fluorescent bulb problems
5. Cheap and efficient white light LEDs new design described in AIPs Journal of Applied Physics
6. GEN highlights increasing use of digital gene expression profiling
7. Distinguishing single cells with nothing but light
8. Concerns about food safety to be spotlighted at U of Minnesota symposium
9. April 2009 Geology and GSA Today media highlights
10. AGU journal highlights -- March 25, 2009
11. Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... Through the generous support of the Breast ... Cancer Research (AACR) is pleased to announce the ... Translational Breast Cancer Research. These grants provide ... designed to accelerate the discovery, development, and application ...
... DC Some nanotechnology fanciers suggest that, like ... will flock or clump together. ... risks as nanotechnology manufacturing increases and the number ... nanoparticle expert Andrew Maynard, chief science advisor to ...
... A modified plastic material greatly improves the ability to ... the gas is prepared for use, according to engineers ... analyzed the new plastics performance. Like a sponge ... permits carbon dioxide or other small molecules to go ...
Cached Biology News:AACR, BCRF award inaugural grants in translational breast cancer research 2AACR, BCRF award inaugural grants in translational breast cancer research 3Nanoparticle exposures happen, says expert 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
(Date:6/2/2015)... SAO PAULO , June 2, 2015   ... leader in biosimilars, today announced that its partner, Celltrion – ... ANVISA – the National Health Surveillance Agency in ... first biosimilar monoclonal antibody approved for use in ... by Hospira. Hospira also markets and sells biosimilar infliximab ...
(Date:6/2/2015)... LOUIS , June 2, 2015   ... Life Science and Technology company, announced today it ... Science to launch genetically engineered human neural ... advance the research of neurological diseases. These new ... provide unique and versatile tools for the study ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... CRANBURY, N.J., Aug. 12 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of subcutaneously administered ... male erectile dysfunction (ED) and female sexual dysfunction (FSD). ... blood plasma levels can be obtained without blood pressure ...
... Health care jobs continue ... industry remains at 20,000 monthly, and health care has one of the the lowest unemployment rates ... feeling the economic pinch more and more. , ... (Vocus) August 12, 2009 -- There is a dichotomy between simultaneous job creation and job ...
... Scientists drew fittingly from Roman mythology when they named ... Janus, who is usually depicted as having two faces ... been fascinated by the tantalizing possibilities of these particles ... and many other devices. However, realizing these applications requires ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 2Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 3Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration 4The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 2The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 3The MedZilla Report for July, 2009 - Health Care Creates 20,000 More Jobs As Economy Hits Insurers 4Capping a two-faced particle gives duke engineers complete control 2
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Phosphorylcholine hapten is conjugated to BSA protein by use of p-diazonium phenylphosphorylcholine....
Viral CMV UL146/vCXC1 Biotinylated Affinity Purified PAb...
Blue Standard is 3-cyano-7-hydroxycoumarin....
Biology Products: